Retrospective Study of the Safety and Efficacy of Suprachoroidal CLS-TA in Combination With Intravitreal Aflibercept for the Treatment of Macular Edema Associated With RVO in Subjects Who Completed Parent Study CLS1003-201

Brief Summary

Detailed Description

This is a non-interventional, retrospective study of up to 6 months for subjects that completed the parent study CLS1003-201. This study is designed to collect data from patients following their parent study exit visit, through either the time of the next treatment for RVO or at least 6 months following the parent study exit visit, whichever occurs first. During this non-interventional retrospective study, the following data will be collected in an online questionnaire (or where required, on paper) provided by Clearside: * Next RVO therapy administered (if applicable), including reason for treatment * Continued documentation of current or changes in medical or ocular conditions following parent study * Concomitant drug or therapy changes * Visual acuity, including details on the method used in the assessment * Central retinal thickness, including details on the equipment used in its determination * Intraocular pressure, including details on the equipment used in its determination Subjects will be selected based on parent study primary investigator's access to their medical records access, following exit from CLS1003-201. Data will also be collected on the total number of patients included in this non interventional study as well as reasons patients were excluded. Data will be summarized from the randomization treatment assignment in the parent study.

Primary Outcomes

Secondary Outcomes

• Mean change from baseline in central subfield thickness(6 months following exit from Parent study)
• Mean change from baseline for intraocular pressure(6 months following exit from Parent study)
• Mean change from baseline in best corrected visual acuity(6 months following exit from Parent study)